Welcome to our dedicated page for Dyne Therapeutics news (Ticker: DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics stock.
Dyne Therapeutics, Inc. (NASDAQ: DYN) is a clinical-stage biotechnology leader advancing targeted therapies for genetically driven neuromuscular diseases through its proprietary FORCE™ platform. This page provides investors, researchers, and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives shaping the company's progress.
Access real-time announcements including clinical trial results, research collaborations, and regulatory filings alongside analysis of pipeline advancements for conditions like myotonic dystrophy and Duchenne muscular dystrophy. Our curated news collection ensures you stay informed about therapeutic innovations leveraging Dyne's novel approach to muscle-targeted oligonucleotide delivery.
Bookmark this page for direct access to earnings reports, scientific presentations, and partnership announcements that demonstrate Dyne's commitment to addressing high unmet needs in neuromuscular care. Regularly updated to reflect the latest developments in their mission to transform treatment paradigms.
Dyne Therapeutics, Inc. (DYN) announced that DYNE-251, its investigational therapy for Duchenne muscular dystrophy (DMD), received FDA orphan drug and rare pediatric disease designations. This marks a significant step as DYNE-251 undergoes evaluation in the Phase 1/2 DELIVER clinical trial. The trial aims to enroll 46 males aged 4 to 16 with DMD mutations suitable for exon 51 skipping. Initial data is expected in the second half of 2023, focusing on safety and dystrophin levels. DYNE-251 uses a novel delivery method targeting muscle cells, showing promising results in preclinical studies, including a favorable safety profile and effective exon skipping.
Dyne Therapeutics (Nasdaq: DYN) announced key developments during the MDA Clinical & Scientific Conference held March 19-22, 2023. The company showcased its global Phase 1/2 clinical trials, ACHIEVE and DELIVER, evaluating DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy (DMD), respectively. Initial data from both trials is expected in the second half of 2023. Additionally, the FORCE™ platform demonstrated successful exon skipping and dystrophin restoration in preclinical models, indicating potential for treating DMD. The company aims to address the urgent need for better therapies in muscle diseases.
FAQ
What is the current stock price of Dyne Therapeutics (DYN)?
What is the market cap of Dyne Therapeutics (DYN)?
